Jazz Pharmaceuticals and AbCellera have entered into a new research collaboration aimed at developing next-generation antibody-based treatments for gastrointestinal (GI) cancers and other difficult-to-treat solid tumors.
The agreement combines Jazz Pharmaceuticals’ growing oncology expertise with AbCellera’s advanced antibody discovery technologies to identify and develop novel T-cell engaging (TCE) multispecific antibodies. The partnership will initially focus on creating new therapies designed to harness the body’s immune system to recognize and destroy cancer cells more effectively.
T-cell engagers have emerged as one of the most promising areas in cancer immunotherapy. These engineered antibodies are designed to bring immune T cells into close contact with cancer cells, triggering a targeted immune response. While the approach has shown success in certain blood cancers, researchers are now working to adapt the technology for solid tumors, where treatment challenges remain significant.
Under the terms of the collaboration, AbCellera will use its proprietary antibody discovery engine and T-cell engager platform to identify and optimize potential drug candidates. The company will work to generate development-ready antibodies that could eventually advance into clinical testing for multiple GI cancers and other solid tumor indications.
The collaboration is expected to strengthen Jazz Pharmaceuticals’ presence in oncology while supporting its broader strategy of developing innovative therapies for patients with serious diseases. Gastrointestinal cancers, including colorectal, gastric, pancreatic, and liver cancers, remain among the leading causes of cancer-related deaths worldwide, highlighting the need for more effective treatment options.
Josh Allen, Chief Scientific Officer for Oncology at Jazz Pharmaceuticals, said the partnership aligns closely with the company’s long-term strategy and expands its efforts in gastrointestinal cancers.
According to Allen, the collaboration builds on Jazz’s existing oncology capabilities and offers an opportunity to advance potentially best-in-class multispecific antibodies into clinical development. He added that the company is committed to delivering meaningful innovation for patients facing cancers with limited treatment options.
AbCellera brings extensive expertise in antibody discovery and engineering to the partnership. Its T-cell engager platform provides a fully integrated development system that spans early discovery through clinical manufacturing. The platform includes proprietary CD3-binding antibodies, specialized costimulatory targeting components, advanced multispecific protein engineering technologies, and high-throughput functional screening tools designed to identify the most promising candidates.
Carl Hansen, founder and Chief Executive Officer of AbCellera, said the company is excited to apply years of experience in T-cell engager development to the collaboration with Jazz.
Hansen noted that T-cell engagers have the ability to drive highly targeted immune activation, potentially improving outcomes compared with existing therapies for gastrointestinal cancers and other solid tumors. He emphasized that the partnership aims to bring forward innovative cancer treatments that could address significant unmet medical needs.
The agreement reflects a broader trend in the biotechnology industry, where pharmaceutical companies are increasingly investing in next-generation immunotherapies to combat cancer. Multispecific antibodies, which can simultaneously interact with multiple biological targets, are attracting growing interest because of their potential to enhance precision and effectiveness while minimizing unwanted side effects.
Although the collaboration remains in the preclinical stage, both companies believe the combination of AbCellera’s technology platform and Jazz’s development expertise could accelerate the creation of new therapies for patients with challenging cancers. If successful, the partnership may contribute to the next wave of immunotherapy innovations aimed at improving survival and quality of life for individuals diagnosed with GI cancers and other solid tumors.